Root Admin Guide Posted January 12, 2017 Root Admin Report Share Posted January 12, 2017 On the horizon, another α-adrenergic agonist, oxymetazoline 1% cream, likely will earn FDA approval in early 2017, predicted Drs. Harper and Webster. Allergan submitted the drug for FDA approval in mid-2016 and expects its Prescription Drug User Fee Act date in the first half of 2017, according to the company. 12th Annual Women's & Pediatric Dermatology Symposium 2016, Dermatology TimesRosacea treatments Dermatologists welcome antibiotics, α-adrenergic agonists and more Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now